Monday, July 13, 2026
Today at a Glance13 articles · 3 sources
Top Stories
- 1Apnimed dreams of IPO to fund launch of sleep apnea pill on FDA's deskMarket AccessFierce Biotech
- 2Bausch + Lomb gives up on glaucoma eye drop hopeful after phase 2 failClinical TrialsFierce Biotech
- 3Insilico’s Chinese partner returns for $177M pact to explore ‘mass market’ CNS indicationMarket AccessFierce Biotech
Key Entities
Companies
Eli LillyGSKHansoh PharmaceuticalMedAirePheast TherapeuticsAntengene
Drugs & Therapies
PHST001ATG-031hepatitis B vaccineCOVID-19 vaccine (mRNA)Oxnimbi
Coverage
- Policy5
- Market Access5
- Clinical Trials3
Sources
STAT News, Fierce Biotech, Endpoints News
Policy
Policy•STAT News•Jul 13, 2026
As states absorb Medicaid funding cuts, family caregivers face financial ruin
background ▾
- •A $1 trillion Medicaid funding cut embedded in the 2025 GOP tax bill takes effect January 1, 2027, and states are preemptively targeting optional family caregiver compensation programs to manage budget pressure.
- •Multiple states are proposing wage cuts of $20+ per hour for family caregivers of individuals with intellectual and developmental disabilities, directly threatening the financial stability of families dependent on these programs.
- •The Trump administration's rhetoric about fraud in family caregiver programs is being used to justify cuts despite the absence of evidence about actual fraud rates, suggesting sustained political pressure on Medicaid services through 2027.
Policy•STAT News•Jul 13, 2026
Opinion: Is there a doctor on board? Yes, and airlines depend on it
background ▾
- •Airlines currently operate without dedicated onboard medical staff and depend structurally on volunteer physician-passengers, creating an asymmetry where the industry benefits operationally while physicians bear clinical and liability responsibility
MedAire
→ Read original articlePolicy•STAT News•Jul 13, 2026
Opinion: The shortage of forensic pathologists is hurting justice, public health, and families
background ▾
- •This is an opinion/commentary piece, not news reporting a specific event, policy change, or clinical development relevant to pharmaceutical industry operations
Policy•Fierce Biotech•Jul 12, 2026
‘How did they get there first?’ Biotechs forced to learn new patent tricks to protect pipelines
background ▾
- •Chinese clinical trial timelines have dropped from 60 to 30 days and cost 50-60% less than U.S. trials, enabling fast-follower strategies that undercut Western innovators
- •Patent attorneys now routinely advise biotechs on stealth operations, misdirection tactics, and defensive patent filings to obscure R&D direction and prevent competitors from identifying targets early
Pheast TherapeuticsAntengeneSanté VenturesPHST001ATG-031
→ Read original articlePolicy•STAT News•Jul 10, 2026
Nominee for key federal health role has a history of questioning vaccines
background ▾
- •A vaccine-skeptical nominee would, if confirmed, directly oversee U.S. vaccine stockpiles and emergency response countermeasures—representing a significant policy shift in federal vaccine governance under Kennedy's HHS leadership
hepatitis B vaccineCOVID-19 vaccine (mRNA)
→ Read original articleMarket Access
Market Access•Fierce Biotech•Jul 12, 2026
Apnimed dreams of IPO to fund launch of sleep apnea pill on FDA's desk
background ▾
- •Oxnimbi represents a potentially significant market opportunity as the first non-obesity-limited prescription drug for OSA (80M patients in U.S. alone), addressing the standard CPAP therapy gap
- •FDA approval timing is critical; the filing was submitted in April 2025 with strong phase 3 efficacy data, but approval decision has not yet been announced
- •IPO execution faces biotech market volatility risks and will require sufficient capital to support both regulatory approval and commercial infrastructure (CCO already hired from Pfizer)
ApnimedEli LillyShionogiOxnimbiAD109Zepbound
→ Read original articleMarket Access•Fierce Biotech•Jul 13, 2026
Insilico’s Chinese partner returns for $177M pact to explore ‘mass market’ CNS indication
background ▾
- •CMS commits $177M in milestone payments plus royalties to Insilico for an unnamed CNS asset with claimed 'mass-market' potential and innovative mechanism of action, signaling confidence in AI-identified drug candidates
- •This is Insilico's second partnership with CMS in five months and part of a broader dealmaking streak including $2.75B with Eli Lilly, $2.5B with SK Biopharmaceuticals, and $888M with Servier—establishing Insilico as a major AI drug discovery platform with strong pharma validation
- •Watch for: disclosure of the specific CNS indication and mechanism, clinical development timeline, and whether CMS' commercialization network in China translates PandaOmics candidates into actual market access and revenue
China Medical System HoldingsInsilico MedicineEli LillyPandaOmicsNLRP3 inhibitor
→ Read original articleMarket Access•Endpoints News•Jul 11, 2026
Deals, deals, deals; Biohaven takes on Eli Lilly; and more
background ▾
- •Multiple M&A or partnership activities occurred in the biotech sector during the reporting period
BiohavenEli Lilly
→ Read original articleMarket Access•Fierce Biotech•Jul 10, 2026
KKR-backed Allyntra debuts to serve medtech industry as it announces new CEO
background ▾
- •KKR is consolidating its medtech CDMO investments under a unified Allyntra platform to capture precision-manufacturing and supply-chain value in medical devices
KKRPrecipartAllyntra
→ Read original articleMarket Access•Endpoints News•Jul 10, 2026
US biotechs turn secretive as they fear competition from rising Chinese industry
background ▾
- •US biotech companies are implementing heightened confidentiality practices around pipeline and R&D activities due to perceived competitive threats from Chinese biotech firms
Junevity
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Jul 10, 2026
Bausch + Lomb gives up on glaucoma eye drop hopeful after phase 2 fail
background ▾
- •BL1107 failed primary and key secondary endpoints in phase 2, prompting complete program discontinuation despite earlier phase 1/2a promise
- •Bausch + Lomb is pivoting its Whitecap acquisition investment toward WB006 (implant formulation) for geographic atrophy rather than glaucoma, significantly changing the strategic value of the $28M deal
- •Watch for WB006 phase 1 data readout before 2028 trial initiation and the Ripple Therapeutics collaboration progress, as this represents Bausch + Lomb's repositioned bet on the alpha-2B agonist platform
Bausch + LombWhitecap BiosciencesRipple TherapeuticsBL1107WB006Vyzulta
→ Read original articleClinical Trials•Fierce Biotech•Jul 10, 2026
GSK sees phase 3 win for Hansoh-partnered ADC in China as validating its ‘priority asset’
background ▾
- •Ris-rez achieved OS benefit in phase 3 SCLC trial in China—first positive OS data for any B7-H3 ADC across any tumor type, validating GSK's priority asset designation
- •GSK is advancing ris-rez in its own phase 3 programs in extensive-stage SCLC (readout 2027) and genitourinary cancer, plus mo-rez in five planned late-stage trials following encouraging phase 1 ovarian/endometrial data
GSKHansoh Pharmaceuticalrisvutatug rezetecan (ris-rez)mo-rez
→ Read original articleClinical Trials•Endpoints News•Jul 10, 2026
Hansoh meets Phase 3 SCLC goal; FDA approves Sanofi on-body injector
background ▾
- •Hansoh's Phase 3 trial for risvutatug rozetacan (ADC) in SCLC met its primary endpoint, advancing a GSK-partnered asset in an oncology area with high unmet need
Hansoh PharmaceuticalGSKSanofirisvutatug rozetacan
→ Read original article